IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

LOGLIO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.485
NA - Nord America 1.372
EU - Europa 1.310
SA - Sud America 173
AF - Africa 26
OC - Oceania 8
Totale 4.374
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.332
SG - Singapore 478
CN - Cina 474
GB - Regno Unito 416
IT - Italia 262
HK - Hong Kong 165
DE - Germania 159
BR - Brasile 137
BD - Bangladesh 117
RU - Federazione Russa 109
SE - Svezia 90
FR - Francia 76
VN - Vietnam 76
IN - India 57
NL - Olanda 45
DK - Danimarca 35
IE - Irlanda 35
CA - Canada 26
TR - Turchia 22
ID - Indonesia 18
JP - Giappone 18
AR - Argentina 17
FI - Finlandia 17
BE - Belgio 14
CI - Costa d'Avorio 11
AT - Austria 9
PL - Polonia 9
IQ - Iraq 8
UA - Ucraina 8
ES - Italia 7
KR - Corea 7
UZ - Uzbekistan 7
AU - Australia 6
PH - Filippine 6
PK - Pakistan 5
TN - Tunisia 5
TW - Taiwan 5
ZA - Sudafrica 5
CH - Svizzera 4
CL - Cile 4
CO - Colombia 4
MX - Messico 4
MY - Malesia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
EC - Ecuador 3
HN - Honduras 3
LU - Lussemburgo 3
CZ - Repubblica Ceca 2
EG - Egitto 2
JO - Giordania 2
KW - Kuwait 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
NI - Nicaragua 2
PS - Palestinian Territory 2
PY - Paraguay 2
SA - Arabia Saudita 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GR - Grecia 1
HU - Ungheria 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PG - Papua Nuova Guinea 1
PT - Portogallo 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
TT - Trinidad e Tobago 1
Totale 4.374
Salva come PNG Salva come JPEG
Città #
Southend 386
Singapore 312
Ashburn 208
Chandler 189
Hong Kong 150
Milan 118
Beijing 98
San Jose 81
Frankfurt am Main 80
Dallas 63
Los Angeles 49
Ann Arbor 46
Council Bluffs 44
Princeton 43
New York 39
Fairfield 36
Dublin 35
Santa Clara 30
Wilmington 30
Moscow 25
Bengaluru 24
Buffalo 24
Hanoi 24
Lauterbourg 24
Dearborn 22
Grafing 22
Hefei 21
Houston 21
Boardman 20
Des Moines 20
Ho Chi Minh City 18
São Paulo 17
Piscataway 16
Woodbridge 16
Columbus 15
Guangzhou 15
Nanjing 15
The Dalles 15
Tokyo 15
Brussels 14
Istanbul 14
Toronto 14
Hangzhou 13
Rome 13
Seattle 12
Abidjan 11
Cangzhou 10
Fremont 10
Helsinki 10
Redwood City 10
Berlin 8
Shanghai 8
Changsha 7
Gorla Maggiore 7
Jakarta 7
Tianjin 7
Brooklyn 6
Fuzhou 6
Nanchang 6
Nuremberg 6
Phoenix 6
Roubaix 6
San Francisco 6
Seoul 6
Turin 6
Zhengzhou 6
Central District 5
Cinisello Balsamo 5
Jiaxing 5
Jinan 5
Lappeenranta 5
Munich 5
Naples 5
New Taipei City 5
Rio de Janeiro 5
Shenyang 5
Vienna 5
Warsaw 5
Washington 5
Belo Horizonte 4
Bologna 4
Cambridge 4
Chennai 4
Dong Ket 4
Düsseldorf 4
Hebei 4
Kunming 4
Orem 4
Ottawa 4
Shenzhen 4
Tashkent 4
Wroclaw 4
Atlanta 3
Baghdad 3
Bexley 3
Buenos Aires 3
Bühl 3
Caxias do Sul 3
Chicago 3
Chongqing 3
Totale 2.802
Salva come PNG Salva come JPEG
Nome #
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 251
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy 245
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 243
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy 221
Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance 211
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 211
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients 200
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis : a case report of 3 patients 198
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients 196
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 196
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 188
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients 183
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B 165
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B 159
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs) 159
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide 151
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B 149
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis 142
Incidence and Predictors of Complications Following Percutaneous Liver Biopsy: A Large Italian Multicentre Study. 139
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro 132
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population 131
Hepatitis D–how is the fight against this foe going? 125
Treatment of hepatitis B : is there still a role for interferon? 121
How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals? 115
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension 103
Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients 95
Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B 53
Novel Therapies That May Cure Chronic Hepatitis B Virus. 53
Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study 13
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? 13
Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study 10
Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database 10
The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm 8
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis 5
Baseline HDV-RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study 4
Totale 4.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.926
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.926
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 0 0 0 0 0 11 71
2021/2022319 22 15 26 12 16 11 12 17 18 52 19 99
2022/2023429 54 67 57 52 37 82 3 20 26 6 12 13
2023/2024295 8 21 3 22 60 10 46 21 20 9 35 40
2024/2025833 38 73 14 88 53 32 41 69 33 116 80 196
2025/20261.788 206 106 187 131 149 114 212 66 163 134 320 0
Totale 4.598